Univariate and multivariate analysis for PFS
| . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| P . | HR (95% CI) . | P . | HR (95% CI) . | |
| Age ≥60 y | .002 | 1.33 (1.1-1.6) | .003 | 2.98 (1.7-6.8) |
| Stage III-IV | .069 | 1.68 (0.88-3.2) | — | — |
| Extranodal sites ≥2 | .003 | 1.73 (1.2-2.6) | .082 | 3.2 (1.7-5.1) |
| ECOG >2 | .0003 | 1.9 (1.4-2.7) | .001 | 4.3 (2.1-6.8) |
| Bone marrow involvement | .223 | 1.3 (0.8-1.9) | — | — |
| B symptoms | .017 | 1.5 (1.0-2.1) | .092 | 2.31 (1.8-3.5) |
| LDH > ULN | .005 | 1.62 (1.1-2.2) | .071 | 1.73 (1.4-3.1) |
| Hemoglobin <12 g/dL | .018 | 1.48 (1-2) | .123 | 0.75 (0.2-2.4) |
| Platelets <150 000/mm3 | .438 | 1.1 (0.8-1.6) | — | — |
| Monocytes <800/mm3 | .033 | 1.5 (2.6) | .082 | 1.31 (0.9-3.3) |
| ANC >6500/mm3 | .173 | 1.26 (0.9-1.7) | — | — |
| β2M > ULN | .003 | 2.9 (1.4-5.8) | .002 | 3.21 (2.2-6.5) |
| CRP > ULN | .004 | 2.9 (1.4-6.1) | .003 | 1.9 (1.2-4.6) |
| . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| P . | HR (95% CI) . | P . | HR (95% CI) . | |
| Age ≥60 y | .002 | 1.33 (1.1-1.6) | .003 | 2.98 (1.7-6.8) |
| Stage III-IV | .069 | 1.68 (0.88-3.2) | — | — |
| Extranodal sites ≥2 | .003 | 1.73 (1.2-2.6) | .082 | 3.2 (1.7-5.1) |
| ECOG >2 | .0003 | 1.9 (1.4-2.7) | .001 | 4.3 (2.1-6.8) |
| Bone marrow involvement | .223 | 1.3 (0.8-1.9) | — | — |
| B symptoms | .017 | 1.5 (1.0-2.1) | .092 | 2.31 (1.8-3.5) |
| LDH > ULN | .005 | 1.62 (1.1-2.2) | .071 | 1.73 (1.4-3.1) |
| Hemoglobin <12 g/dL | .018 | 1.48 (1-2) | .123 | 0.75 (0.2-2.4) |
| Platelets <150 000/mm3 | .438 | 1.1 (0.8-1.6) | — | — |
| Monocytes <800/mm3 | .033 | 1.5 (2.6) | .082 | 1.31 (0.9-3.3) |
| ANC >6500/mm3 | .173 | 1.26 (0.9-1.7) | — | — |
| β2M > ULN | .003 | 2.9 (1.4-5.8) | .002 | 3.21 (2.2-6.5) |
| CRP > ULN | .004 | 2.9 (1.4-6.1) | .003 | 1.9 (1.2-4.6) |